Tonix claims data highlight high economic, medical burden of fibromyalgia
Tonix Pharmaceuticals (NASDAQ:TNXP) presented a retrospective U.S. real-world claims analysis at the ISPOR 2026 annual meeting, detailing a heavy economic and clinical burden among adults diagnosed with fibromyalgia.
-640x360.webp&w=3840&q=75)









